Pierre-Guillaume Poureau

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

Gerald W. Prager, Marwan Fakih, Fortunato Ciardiello et al. · New England Journal of Medicine · 2023 · 428 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Regorafenib–avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial

Sophie Cousin, Coralie Cantarel, Jean‐Philippe Guégan et al. · European Journal of Cancer · 2022 · 50 citations · Full text

Medicine, Oncology, Pharmacology +7

Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study.

Josep Tabernero, Gerald W. Prager, Marwan Fakih et al. · Journal of Clinical Oncology · 2023 · 48 citations · Full text

Medicine, Oncology, Pharmacology +12

MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancer

Émeric Boisteau, Alexandra Lespagnol, Marie de Tayrac et al. · Clinics and Research in Hepatology and Gastroenterology · 2022 · 12 citations

Medicine, Molecular Medicine, Oncology +13

613P Effect of prior use of anti-VEGF agents on overall survival in patients with refractory metastatic colorectal cancer: A post-hoc analysis of the phase III SUNLIGHT trial

Gerald W. Prager, Marwan Fakih, Fortunato Ciardiello et al. · Annals of Oncology · 2023 · 10 citations · Full text

Medicine, Oncology, Pharmacotherapy +17